1. The company reported $1.768 billion in sales for the first quarter, representing a 6 percent increase in operational revenue growth compared to the prior year period.
2. Boston Scientific delivered $0.21 first quarter adjusted earnings per share, a growth of 6 percent from the prior year period.
3. The company’s cardiovascular revenue grew 10 percent. Its rhythm management revenue grew 4 percent and its medsurg revenue grew 4 percent.
4. Boston Scientific expanded its revenue by 6 percent in Europe and 7 percent in Asia, the Middle East and Africa.
5. The company also added to its endoscopy portfolio with the acquisition of endoscopic ultrasound company Xlumena and the launch of the next generation SPYGLASS DS Direct Visualization System.
More articles on gastroenterology:
5 most read GI articles – April 20 to April 24
Stretta therapy proves safe for bariatric patients with chronic GERD
PENTAX Medical names new CMO, COO of the Americas
